Patent Assignment
Reel/Frame 023845/0940
Change of Name
Recorded: 2010-01-26
Pages: 23
Assignor
MERCK & CO., INC.
Executed: 2009-11-02
Assignee
MERCK SHARP & DOHME CORP.
126 EAST LINCOLN AVENUE, RAHWAY, NEW JERSEY, 07065
Covered Properties
(165)
Benzothiophene Hydroxamic Acid Derivatives
Phenyl ethyne compounds
Application:
11/918,993 →
Publication:
US US20090306115A1
Amidopropoxyphenyl Orexin Receptor Antagonists
Application:
11/887,666 →
Publication:
US US20080262046A1
Human calcium sensitive potassium channel beta3 subunit proteins, encoding nucleic acid and uses thereof
Application:
11/903,092 →
Publication:
US US20090117590A1
Benzothiophene Derivatives
VLA-4 Antagonists
Application:
11/887,701 →
Publication:
US US20090069376A1
Human Niemann Pick C1-Like 1 Gene (NPC1L1) Polymorphisms and Methods of Use Thereof
Application:
11/887,346 →
Publication:
US US20090192135A1
Substituted Spirochromanone Derivatives
Substituted Diazepan Orexin Receptor Antagonists
Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity
Application:
11/919,308 →
Publication:
US US20090306037A1
Peptide Conjugate Compositions and Methods for the Prevention and Treatment of Alzheimer's Disease
D-Homoandrosta-17-Yl Carbamate Derivatives as Selective Glucocorticoid Receptor Ligands
Tyrosine kinase inhibitors
Application:
11/919,758 →
Publication:
US US20090156617A1
Aminocyclohexanes as Dipeptidyl Peptidase-Iv Inhibitors for the Treatment of Diabetes
Hiv Integrase Inhibitors
Proline bis-amide orexin receptor antagonists
Application:
11/920,596 →
Publication:
US US20090118200A1
Antibiotic compounds
Application:
11/975,514 →
Publication:
US US20080242597A1
Antibiotic compounds
Application:
11/975,537 →
Publication:
US US20080132500A1
Method for identifying modulators of NOAH10 useful for treating Alzheimer's disease
Application:
11/919,903 →
Publication:
US US20090068678A1
Hcv NS3 Protease Inhibitors
Method for improving the immunogenicity of plasmodium antigens
Application:
11/919,610 →
Publication:
US US20090047303A1
1-Hydroxycycloalkanecarboxamide Derivatives
Inhibitors of Janus Kinases
Tyrosine Kinase Inhibitors
Application:
12/308,432 →
Publication:
US US20100267707A1
Aryl-Fused Spirocyclic Compounds
Novel Human Acidic Mammalian Chitinase and Use Thereof
Application:
12/227,719 →
Publication:
US US20090191552A1
Substituted 4-Hydroxypyrimidine-5-Carboxamides
Benzyl-Substituted Quinolone M1 Receptor Positive Allosteric Modulators
Ophthalmic Compositions for Treating Ocular Hypertension
Application:
12/308,164 →
Publication:
US US20090281154A1
Substituted Pyrazoles as Ghrelin Receptor Antagonists
Application:
12/227,545 →
Publication:
US US20090253673A1
Rapid method to determine inhibitor sensitivity of NS3/4A protease sequences cloned from clinical samples
Application:
12/308,010 →
Publication:
US US20090203008A1
Benzaepinones as Sodium Channel Blockers
Hcv NS3 Protease Inhibitors
Eukaryotic Cell Display Systems
Automated Determination of Chlamydia Infection-Forming Units
Application:
12/309,668 →
Publication:
US US20090317840A1
Kidney Toxicity Biomarkers
Application:
12/308,918 →
Publication:
US US20090298073A1
Conjugates and Compositions for Cellular Delivery
2-Substituted Proline Bis-Amide Orexin Receptor Antagonists
Application:
12/302,122 →
Publication:
US US20100029736A1
Sulfonylated Piperazines as Cannabinoid-1 Receptor Modulators
Application:
12/310,221 →
Publication:
US US20090247499A1
Tyrosine Kinase Inhibitors
Bridged diazepan orexin receptor antagonists
1-Hydroxy Naphthyridine Compounds as Anti-Hiv Agents
Application:
12/373,907 →
Publication:
US US20100056516A1
Phosphorus Derivatives as Histone Deacetylase Inhibitors
Substituted Diazepan Orexin Receptor Antagonists
Application:
12/309,239 →
Publication:
US US20090192143A1
Novel Sulfonamidomethylphosphonate Inhibitors of Beta-Lactamase
Application:
12/301,793 →
Publication:
US US20100317625A1
Novel Inhibitors of Beta-Lactamase
Novel Lactic Acid Formulation of Mk-0457 Useful For The Treatment of Cancer
Application:
12/309,550 →
Hydroxymethyl Pyrrolidines as Beta 3 Adrenergic Receptor Agonists
CB-1 receptor modulator formulations
Application:
12/386,403 →
Publication:
US US20090264476A1
Cb-1 Receptor Modulator Formulations
1B20 PCSK9 Antagonists
1D05 PCSK9 Antagonists
Process for Preparing Chiral Dipeptidyl Peptidase -Iv Inhibitor Intermediates
Acylated piperidine derivatives as melanocortin-4 receptor modulators
Application:
12/311,006 →
Publication:
US US20090253744A1
Estrogen Receptor Modulators
Optimized Expression of Hpv 58 L1 in Yeast
Peptide compounds for treating obesity and insulin resistance
Application:
12/287,211 →
Publication:
US US20090104210A1
Pyridyl Amide T-Type Calcium Channel Antagonists
Diaryl Substituted Alkanes
5,6,Fused Pyrrolidine Compounds Useful as Tachykinin Receptor Antagonists
Application:
12/226,294 →
Publication:
US US20090286777A1
Compounds and Methods for Leukotriene Biosynthesis Inhibition
Process for the Synthesis of (+)and (-)-1 Aryl-3-Azabicyclo(3.1.0) Hexanes
Application:
12/226,801 →
Publication:
US US20100204486A1
Pro-Drugs of Tertiary Alcohols
Application:
12/226,934 →
Publication:
US US20090137529A1
Substituted Esters as Cannabinoid-1 Receptor Modulators
Application:
12/227,035 →
Publication:
US US20120135975A1
Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
Application:
12/226,050 →
Publication:
US US20090170891A1
Diazepan Orexin Receptor Antagonists
Fluorescent compounds that bind to histone deacetylase
Application:
12/313,799 →
Publication:
US US20090156825A1
Tyrosine Kinase Inhibitors
Process for the Preparation of Caprolactam Cgrp Antagonist
Process for the Preparation of Cgrp Antagonist
Process for the Preparation of Pyridine Heterocycle Cgrp Antagonist Intermediate
Application:
12/226,126 →
Publication:
US US20090176986A1
Substituted 3-Alkyl and 3-Alkenyl Azetidine Derivatives
Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds and Methods of Use
Substitued [1,2,4]Triazolo[1,5-a]Pyrazines as Dipeptidyl Peptidase-Iv Inhibitors for the Treatment or Prevention of Diabetes
Inhibitors of Akt Activity
Application:
61/159,230 →
Histone Deacetylase Inhibitors for the Treatment of Neurodegeneration
Application:
12/227,055 →
Publication:
US US20090325862A1
Disubstituted Aniline Compounds
Thiazole Derivatives as CXCR3 Receptor Modulators
Application:
12/085,650 →
Publication:
US US20090143413A1
Process for Synthesizing 2-Phenyl-1H-Phenanthro[9,10-D]Imidazole Derivative
Application:
12/085,258 →
Publication:
US US20090203922A1
Tricyclic Compounds Useful as Inhibitors of Kinases
Methods for Predicting Treatment Response Based on the Expression Profiles of Protein and Transcription Biomarkers
Octahydropyrano[3,4-C]Pyrrole Tachykinin Receptor Antagonists
Application:
12/086,810 →
Publication:
US US20090048248A1
Method of using SAHA and Erlotinib for treating cancer
Application:
12/150,999 →
Publication:
US US20080221138A1
Taste-Masked Tablets and Granules
Application:
12/087,827 →
Publication:
US US20090136570A1
Methods of Treating Cancers with SAHA, Carboplatin, and Paclitaxel and Other Combination Therapies
Application:
12/084,026 →
Publication:
US US20090105329A1
Salt of an androgen receptor modulator
Application:
12/228,356 →
Publication:
US US20090048283A1
Morpholine Carboxamide Prokineticin Receptor Antagonists
Method for Assessing Airborn Microorganisms
Application:
12/085,738 →
Publication:
US US20090197299A1
Self-Emulsifying Formulations of Cetp Inhibitors
2-Arylthiazole Derivatives as CXCR3 Receptor Modulators
Application:
12/086,361 →
Publication:
US US20100286191A1
Spirocyclic Compounds
Fused Aminopiperidines as Dipeptidyl Peptidase-4 Inhibitors for the Treatment or Prevention of Diabetes
Cetp Inhibitors
Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
Application:
12/086,938 →
Publication:
US US20090042926A1
Pharmaceutical Compositions of Combinations of Dipeptidyl Peptidase-4 Inhibitors with Metformin
CGRP Antagonist Salt
Application:
12/086,670 →
Publication:
US US20100286122A1
Quinolizinyl Deriatives Useful as Inhibitors of P-38 Kinase
Application:
12/085,419 →
Publication:
US US20090088436A1
Cetp Inhibitors
Niacin Receptor Agonists, compositions Containing Such Compounds and Methods of Treatment
Application:
11/992,069 →
Publication:
US US20110028462A1
Tyrosine Kinase Inhibitors
Application:
12/083,818 →
Publication:
US US20090291941A1
Potassium Channel Inhibitors
Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors
Application:
12/083,746 →
Publication:
US US20090131423A1
Potassium Channel Inhibitors
4-Oxo-1-3-Substituted Phenyl-1,4-Dihydro-1,8-Napthyridene-3-Carboxamide Phosphodiesterase-4 Inhibitor and a Method of Preparing Same
Application:
12/083,931 →
Publication:
US US20090105479A1
Methods and Compositions for Treating Cancer
Application:
11/992,798 →
Publication:
US US20100166731A1
Cetp Inhibitors
Hiv Integrase Inhibitors
Application:
12/084,158 →
Publication:
US US20090312335A1
Piperdine Glycine Transporter Inhibitors
Combination of a Dipeptidyl Peptidase-4 Inhibitor and an Anti-Hypertensive Agent for the Treatment of Diabetes and Hypertension
Application:
11/992,912 →
Publication:
US US20090156579A1
Imidazolidinone Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
Diphenylmethane Derivatives as Inhibitors of Leukotriene Biosynthesis
Application:
12/084,374 →
Publication:
US US20090258885A1
Indole Orexin Receptor Antagonists
Application:
12/085,342 →
Publication:
US US20090088452A1
Histone Deacetylase Inhibitors with Aryl-Pyrazolyl-Motifs
Substituted Nicotinamide Compounds
Application:
12/084,272 →
Publication:
US US20090105264A1
Spirolactam Aryl Cgrp Receptor Antagonists
Bicyclic Spirohydantoin Cgrp Receptor Antagonists
Spirohydantoin Tricyclic Cgrp Receptor Antagonists
Spirolactam Bicyclic Cgrp Receptor Antagonists
Spirohydantoin Aryl Cgrp Receptor Antagonists
Spirolactam Tricyclic Cgrp Receptor Antagonists
Tyrosine kinase inhibitors
Application:
12/148,649 →
Publication:
US US20080274107A1
Method of Generating Amorphous Solid for Water-Insoluble Pharmaceuticals
Application:
12/085,254 →
Publication:
US US20090111997A1
A Pharmaceutical Composition Comprising Oxyntomodulin Derivatives and a Method for Reducing Body Weight Using the Composition
Antigen-Binding Proteins Targeting S. Aureus Orf0657n
Application:
12/223,110 →
Publication:
US US20110091480A1
Inhibitors of Fatty Acid Synthase (Fas)
Application:
12/223,305 →
Publication:
US US20090048276A1
Triazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1
Fluorinated Arylamide Derivatives
Application:
12/087,624 →
Publication:
US US20090012075A1
Aminocyclohexanes as Dipeptidyl Peptidase-Iv Inhibitors for the Treatment or Prevention of Diabetes
2,5 Diaza-Bicyclo [2.2.1] Heptane Derivatives as Calcium Channel Blockers
Application:
12/087,932 →
Publication:
US US20090005389A1
Jak2 Tyrosine Kinase Inhibition
Application:
12/223,043 →
Publication:
US US20090062302A1
Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists
Application:
12/087,141 →
Publication:
US US20090042854A1
Fused Triazole Tachykinin Receptor Antagonists
Application:
12/087,187 →
Publication:
US US20090221611A1
Hydroxyalkylarylamide Derivatives
Application:
12/087,623 →
Publication:
US US20090062297A1
Ret Tyrosine Kinase Inhibition
Application:
12/223,042 →
Publication:
US US20090227598A1
Substituted Piperdines as Calcium Channel Blockers
Application:
12/086,740 →
Publication:
US US20090048227A1
Cetp Inhibitors
Cholesteryl Ester Transfer Protein Inhibitors
1,3-Oxazolidin-2-One Derivatives Useful as Cetp Inhibitors
Pyridine derivative potassium channel inhibitors
Polymer Formulations of Cetp Inhibitors
Tertiary Amine Derivative Potassium Channel Inhibitors For The Treatment Of Cardiovascular Diseases
Application:
12/223,356 →
Publication:
US US20090030043A1
Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
Potassium Channel Inhibitors
Potassium Channel Inhibitors
Aminotetrahydropyrans as Dipeptidyl Peptidase-Iv Inhibitors for the Treatment or Prevention of Diabetes
Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
Application:
12/223,492 →
Publication:
US US20090062269A1
Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators
Application:
12/223,556 →
Publication:
US US20090030012A1
Amidoethylthioether Orexin Receptor Antagonists
Application:
12/225,375 →
Publication:
US US20090105318A1
Inhibitors of Histone Deacetylase
Novel Crystalline Forms of Antidiabetic Compounds
Application:
12/224,527 →
Publication:
US US20090264473A1
Display Control of a Tachograph
Application:
11/913,906 →
Publication:
US US20090019387A1
Ophthalmic Compositions for Treating Ocular Hypertension
Application:
12/225,026 →
Publication:
US US20090062280A1
Ophthalmic compositions for treating ocular hypertension
Application:
12/220,306 →
Publication:
US US20080287489A1
Method For Genetic Selection Of High-Plasmid Producing E. Coli Clones
Application:
12/225,139 →
Publication:
US US20090081681A1
Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds and Methods of Use
Somatostatin Agonists
Application:
12/225,027 →
Publication:
US US20090258853A1
Substituted Imidazole-4-Carboxamides as Cholecystokinin -1 Receptor Modulators
Substituted Imidazole 4-Carboxamides as Cholecystokinin-1 Receptor Modulators
Substituted Imidazole 4-Carboxamides as Cholecystokinin-1 Receptor Modulators
Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use
Application:
09/888,304 →
Publication:
US US20070092526A1
Treatment for Cardiovascular Disease
Monoclonal antibodies for human cytochrome p450 3a4 and human cytochrome p450 2c9
Application:
10/049,035 →
Influenza virus vaccine
Application:
10/794,646 →
Publication:
US US20040223976A1
Substituted hydrazine derivatives
Application:
09/948,848 →
Publication:
US US20020120149A1
Related Assignments
(3)
Other recorded transfers of the patents in this record — the chain of ownership.
Merger
Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
Change of Name
Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
Merger
Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →